Colorado Prescription Drug Affordability Review Board & Advisory Council
Colorado’s Prescription Drug Affordability Board (PDAB), established under Senate Bill 21-175 and updated under House Bill 23-1225, is a Type-1 Board within the Division of Insurance that has the authority to review prescription drug costs and evaluate their impact on Coloradans through affordability reviews of prescription drugs. The Board may then recommend ways to address those costs and may set an upper payment limit for certain prescription drugs.
PDAB Listserv
To receive PDAB and PDAAC updates directly in your inbox, click here. To subscribe, you will need to enter your email and then choose Updates From Divisions > Division of Insurance > Division of Insurance Prescription Drug Affordability Board.
PDAB Meetings
The next PDAB meeting will be held on Friday, March 7, 2025 from 10 am - 1 pm MT.
PDAAC Meetings
The next PDAAC meeting will be held on Thursday, January 23, 2025 from 9 am - 12 pm MT.
Register for January 23 PDAAC Meeting
The PDAAC is currently recruiting new council members to represent Labor unions and Carriers. If you are interested in serving a 3-year term on the PDAAC, please fill out the linked application.
Office Hours
Office hours are an informal space for stakeholders to ask questions about PDAB processes and to provide resources for stakeholders to testify during rulemaking hearings.
The next office hour will be held on Tuesday, January 28, 2025 from 12-1 pm MT. Please note that the January 14 office hour is cancelled.
PDAB Rulemaking
Enbrel UPL rulemaking will begin during the March 7 PDAB meeting (please note: this is a delay from the original plan to hold the first rulemaking hearing on January 17, 2025). The Board anticipates holding at least 3 rulemaking hearings for each drug. For more information on PDAB rulemaking and how to provide testimony during a PDAB rulemaking hearing, please visit the linked PDAB Rulemaking Guide.
- 2024/2025 PDAB Rulemaking
- Adopted Rules, Policies, & Resolutions
- Submitted Written Testimonies
- Verbal Testimony Sign Up: Coming Soon
Providing Public Comment
The PDAB welcomes general public comments during PDAB meetings. Comments are limited to 2 minutes per person. Public comment is not a time for the Board to interact with the public.
- Verbal Public Comment: To provide verbal comments, please fill out the sign up form that will be provided at each meeting. Public comments will be limited to 2 minutes per person.
- Written Public Comment: To provide written comments about general PDAB business or agenda items, please email dora_ins_pdab@state.co.us. Written comments will be accepted up to 48 hours before each meeting. Comments submitted after the 48-hour deadline will be considered for the following meeting.
Providing Testimony
Verbal or written testimony occurs only during PDAB rulemaking hearings and will be included in the rulemaking record. The Board may ask questions of stakeholders during their testimony. Visit the PDAB Rulemaking Guide for more information on testifying at a PDAB rulemaking hearing.
- Verbal Testimony: To provide verbal testimony, please fill out the testimony sign up form: Coming Soon. Verbal testimony may be limited in duration.
- Written Testimony: Coming soon.
- Previous PDAB Activities
- PDAB Members
- Dr. Sami Diab, MD of Greenwood Village, Colorado
- Dr. Amy Gutierrez, PharmD of Aurora, Colorado
- Catherine Harshbarger, RN, MHA of Holyoke, Colorado
- Board Chair, Dr. Gail Mizner, MD, FACP, AAHIVS of Snowmass Village, Colorado
- Dr. James Justin VandenBerg, PharmD, BCPS of Denver, Colorado
- PDAAC Members
- Kim Bimestefer, Executive Director of HCPF
- Gail DeVore, representing health care consumers
- Sarita Parikh, representing health care consumers
- Bob Mulch, representing statewide health care advocacy organizations
- PDAAC Chair, Dr. Kimberley Jackson, representing health care consumers living with chronic conditions
- Open position representing labor unions
- PDAAC Vice Chair, Nathan Wilkes, representing employers
- Open position representing carriers
- Marc Reese, representing PBMs
- Dr. Richard Miranda, representing health care professionals with prescribing authority
- Dr. Brett McQueen, representing research organizations
- Katelin Lucariello, representing brand name manufacturers
- Fayez Aziz, representing generic manufacturers
- Ingrid Pan, representing pharmacists
- Leah Lindahl, representing wholesalers
- Conflicts of Interest